Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Requests Antidepressant Labeling Add Warning On Suicidality

This article was originally published in The Pink Sheet Daily

Executive Summary

The public health advisory and labeling change request follows an advisory committee recommendation for a stronger warning on the possible risks of the medications. The warning encourages health care providers to monitor patients closely for suicidal behavior although a link between the medications and suicide has not been established.

You may also be interested in...



UK Declines To Prosecute GSK Over Paxil Risk Information

MHRA determines law was insufficient to warrant criminal prosecution.

UK Declines To Prosecute GSK Over Paxil Risk Information

MHRA determines law was insufficient to warrant criminal prosecution.

Pfizer Zoloft Ad Cited By FDA For Omitting Suicide Risk

FDA's ad review division objects to an October print ad for the antidepressant that failed to mention the risk of suicidality and clinical worsening. The ad's brief summary referenced information from outdated labeling, the agency says.

Related Content

Topics

UsernamePublicRestriction

Register

PS058907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel